CluePoints has been awarded best technological development in clinical trials in the 2019 Scrip Awards. The company’s Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software was recognized for the essential role it plays in improving clinical trials. The solution can help drive the quality, accuracy, and integrity of clinical trial data both during and after study conduct, improving patient safety and increasing productivity, efficiency and cost-effectiveness.
“CluePoints® has been a pioneer in the field of Risk-Based Monitoring over the last 7 years; we continually enhance our Risk-Based Quality Management Solution to ensure that it remains both disruptive and relevant in today’s ever-changing clinical trial space. For the industry to acknowledge the value that CluePoints offers to sponsors, CROs and Clinical Technology Partners is an honor. We’re thrilled to be recognized for our proactive innovation, quality management vision and transparent approach, which are central to our success,” Patrick Hughes, Chief Commercial Officer of CluePoints said.
There are several factors driving the need for RBx, including regulatory changes that have impacted the industry, forcing organizations to re-examine the mechanisms for maximizing clinical trial data quality and how organizations are structuring themselves is changing. In response, CluePoints is committed to helping companies identify, assess, plan, mitigate, monitor and analyze risk across all elements of clinical trial management to comply with regulatory requirements.
“For the CluePoints’ family, staff, customers and stakeholders, this accolade is the icing on the cake, following global expansion and further award wins,” said Hughes. “The new software release demonstrates CluePoints’ ongoing commitment to continuously evolve its platform and add in features requested by its ever-expanding user base. Further, the solution’s continued ability to pinpoint areas of risk isn’t just enabling a more efficient process for Pharma companies and CROs, it is also ensuring better patient safety throughout the study as areas of concern are identified much earlier than previously capable using traditional processes.”